About CRISPR Therapeutics AG
A gene-editing biotech behind the first approved CRISPR therapy (Casgevy for sickle cell disease). No dividend, high beta (~1.3). Binary event risk around pipeline catalysts and regulatory milestones. Rich premiums reflect biotech uncertainty — CSP sellers must be comfortable with sudden, outsized moves.
Biotechnology